Dr. Klopp Discusses Chemoradiation in Endometrial Cancer

Ann H. Klopp, MD, PhD
Published: Monday, Feb 26, 2018



Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses chemoradiation in endometrial cancer.

Klopp says that the combination of chemotherapy and radiation is the best treatment for patients with stage III endometrial cancer. A trial comparing radiation to chemoradiation showed improved disease-free survival in patients who received chemoradiation. Chemoradiation also reduces the risk of recurrence in the pelvis, which is attributed to the radiation component of the therapy, says Klopp.

In a study comparing chemotherapy with chemoradiation, survival was equivalent, but there was a higher rate of pelvic relapse with chemotherapy alone. This is a symptomatic problem for patients and affects their quality of life, says Klopp.


Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses chemoradiation in endometrial cancer.

Klopp says that the combination of chemotherapy and radiation is the best treatment for patients with stage III endometrial cancer. A trial comparing radiation to chemoradiation showed improved disease-free survival in patients who received chemoradiation. Chemoradiation also reduces the risk of recurrence in the pelvis, which is attributed to the radiation component of the therapy, says Klopp.

In a study comparing chemotherapy with chemoradiation, survival was equivalent, but there was a higher rate of pelvic relapse with chemotherapy alone. This is a symptomatic problem for patients and affects their quality of life, says Klopp.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x